AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.
Levi & Korsinsky, LLP has issued an investor alert for Aquestive Therapeutics, Inc. (NASDAQ: AQST) due to a pending securities class action lawsuit. The lawsuit alleges that Aquestive disseminated misleading statements regarding the regulatory approval timeline for its Anaphylm product, causing AQST shares to drop over 37% on January 9, 2026. Institutional investors with losses between June 16, 2025, and January 8, 2026, are encouraged to evaluate lead plaintiff opportunities.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Aquestive Therapeutics, Inc. (AQST). Institutional investors who held AQST shares between June 16, 2025, and January 8, 2026, are encouraged to evaluate lead plaintiff opportunities due to alleged materially misleading statements about the regulatory approval timeline for their Anaphylm product, which led to a significant stock drop. The deadline to apply for lead plaintiff appointment is May 4, 2026.
AQST STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and its officers. The lawsuit alleges that the company made materially false and misleading statements regarding the timeline for approval and launch of its New Drug Application for Anaphylm. Investors who purchased Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026, are encouraged to join the suit, with a deadline to request lead plaintiff status by May 4, 2026.
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Aquestive Therapeutics, Inc. to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that the company made false and misleading statements regarding the approval and launch timeline for its Anaphylm (dibutepinephrine) sublingual film, failing to disclose significant human-factors risks. Affected investors are encouraged to contact the firm to join the case, with a lead plaintiff deadline of May 4, 2026.
AQST SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP has issued a shareholder alert reminding investors of Aquestive Therapeutics (AQST) about the securities class action deadline on May 4, 2026. The lawsuit concerns investors who purchased AQST securities between June 16, 2025, and January 8, 2026. The firm is investigating claims that Aquestive made false or misleading statements regarding its Anaphylm NDA, failing to disclose significant deficiencies related to human factors, which led to a substantial drop in stock price.
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval timeline for its Anaphylm sublingual film NDA, failing to disclose significant risks related to human factors that would impact regulatory approval. Investors are encouraged to join the case by May 4, 2026, to request lead plaintiff status.
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT
Bernstein Liebhard LLP has issued a shareholder alert for Aquestive Therapeutics, Inc. (AQST) investors regarding an upcoming deadline for a securities fraud class action lawsuit. The lawsuit alleges violations of the Securities Exchange Act of 1934 due to misrepresentations concerning Aquestive's New Drug Application for Anaphylm. Investors who purchased shares between June 16, 2025, and January 8, 2026, are encouraged to inquire about joining the class action.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
Pomerantz LLP has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) regarding alleged securities fraud. Investors who purchased Aquestive securities during the Class Period are encouraged to contact the law firm, with a deadline to apply for lead plaintiff status by May 4, 2026. This action follows a significant drop in Aquestive's stock price after the FDA identified deficiencies that delayed approval for its Anaphylm sublingual film.
AQST Stockholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its officers. The lawsuit alleges that the company made false and misleading statements regarding the approval timeline for its Anaphylm (dibutepinephrine) sublingual film, particularly concerning human factors issues that impacted regulatory approval prospects. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit and have until May 4, 2026, to request to be appointed as lead plaintiff.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure ...
Rosen Law Firm is encouraging purchasers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities during the Class Period of June 16, 2025, to January 8, 2026, to secure legal counsel. The firm reminds investors of the May 4, 2026, lead plaintiff deadline for a class action lawsuit alleging the company made false or misleading statements regarding its New Drug Application for Anaphylm. Investors who suffered damages are urged to contact Rosen Law Firm to explore their options.
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline
Aquestive Therapeutics is facing a federal lawsuit alleging that the company and its CEO made misleading statements to investors regarding the FDA approval timeline for its drug Anaphylm. The lawsuit claims that the company concealed material deficiencies in the New Drug Application, particularly human factors-related issues, which led to a significant stock drop when the FDA disclosed these problems. Investors who purchased Aquestive stock between June 16, 2025, and January 8, 2026, may have legal recourse due to the alleged price correction.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.
Levi & Korsinsky, LLP has issued an investor alert for Aquestive Therapeutics, Inc. (NASDAQ: AQST) regarding a securities fraud lawsuit. Investors who held AQST shares between June 16, 2025, and January 8, 2026, may have lost over 37% as shares dropped on January 9, 2026, due to alleged misleading statements about the regulatory approval timeline for Anaphylm. The lawsuit contends that the company inflated its stock price by misrepresenting the FDA approval process, and the deadline to apply for lead plaintiff is May 4, 2026.
AQST Stockholders Have Rights – If You Lost Money Investing
Robbins LLP reminds investors who purchased Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, about a class action lawsuit. The lawsuit alleges that Aquestive misled investors regarding the approval of its New Drug Application (NDA) for Anaphylm, which ultimately faced deficiencies from the FDA and caused a significant stock price decline. Shareholders have until May 4, 2026, to submit their papers to the court to serve as lead plaintiff.
AQST Shareholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and its officers. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval and launch timeline for its New Drug Application (NDA) for Anaphylm. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of May 4, 2026.
AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors who incurred losses in Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive made misleading statements regarding its New Drug Application for Anaphylm, specifically downplaying human factors issues, leading to a significant stock price drop after the FDA identified deficiencies. Shareholders have until May 4, 2026, to seek lead plaintiff appointment.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased shares between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive and its senior officers made misrepresentations concerning the New Drug Application for Anaphylm. Investors impacted during this period are encouraged to contact Bernstein Liebhard LLP to discuss their legal rights and options.
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before Upcoming Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aquestive Therapeutics, Inc. for investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive gave a false impression about the approval of its New Drug Application for Anaphylm, leading to a significant stock price drop after deficiencies were identified by the FDA. Investors who suffered losses have until May 4, 2026, to apply for lead plaintiff in the lawsuit.
AQST PE Ratio & Valuation, Is AQST Overvalued
Aquestive Therapeutics Inc (AQST) is currently considered overvalued, with its forward PS ratio of 13.90 significantly higher than its five-year average. The fair price for AQST is estimated to be between $0.58 and $2.13, indicating it is overvalued by 89.87% compared to its current price of $4.04. The article also highlights that AQST's P/S ratio of 6.86 is 32.84% above the industry average, which is deemed unsustainable given its 9.67% revenue growth.
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval and launch timeline for its Anaphylm (dibutepinephrine) sublingual film, facing risks related to human factors and concealing their impact on regulatory approval. Investors who suffered losses have until May 4, 2026, to request to be appointed as lead plaintiff.
AQST Investor Alert: Aquestive Therapeutics Faces Securities Fraud Lawsuit
Aquestive Therapeutics, Inc. is facing a class action lawsuit filed by institutional investors alleging securities fraud. The lawsuit claims the pharmaceutical company made false and misleading statements about its financial performance and drug development, leading to investor losses. This case highlights the ongoing challenges pharmaceutical companies face in maintaining investor trust and transparency.
Bragar Eagel & Squire Urges Aquestive Investors to Contact Firm Before Deadline
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Aquestive Therapeutics (NASDAQ:AQST) on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges Aquestive misled investors about the FDA approval status of its Anaphylm drug application, claiming it was on track despite identified deficiencies. The announcement of these deficiencies caused Aquestive's stock price to drop over 37%, leading to investor losses.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.
Levi & Korsinsky, LLP has issued an investor alert for Aquestive Therapeutics, Inc. (NASDAQ: AQST) due to a securities fraud lawsuit. Investors who held AQST shares between June 16, 2025, and January 8, 2026, are encouraged to evaluate lead plaintiff opportunities, as the stock dropped over 37% after alleged misleading statements regarding the regulatory approval of Anaphylm. The lawsuit contends that misrepresentations about Anaphylm's FDA approval timeline inflated AQST's trading price.
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) alleging federal securities law violations. The lawsuit claims that Aquestive Therapeutics made false and misleading statements regarding the approval timeline for their drug Anaphylm, specifically downplaying risks related to human factors. Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, are encouraged to join the case by May 4, 2026.
Aquestive Therapeutics | 8-K: Current report
This document is an 8-K current report filed by Aquestive Therapeutics. It serves as a formal notification to the SEC about significant events that shareholders should know about. The content of the report itself is not provided in the snippet.
Aquestive completes Type A FDA meeting, reaffirms Q3 2026 Anaphylm NDA resubmission
Aquestive Therapeutics has completed a Type A meeting with the FDA, receiving preliminary feedback and reaffirming its plan to resubmit the Anaphylm NDA in Q3 2026. The company and FDA aligned on labeling for potential chewing, and Aquestive has revised product container opening mechanisms which will be tested in human factors studies. Final FDA meeting minutes are anticipated by early May 2026, with concurrent regulatory advancement
FDA Type A meeting guides Aquestive (NASDAQ: AQST) Anaphylm NDA path
Aquestive Therapeutics completed an in-person FDA Type A meeting for its Anaphylm™ sublingual film, used for treating Type 1 allergic reactions. The meeting provided critical preliminary FDA feedback on pharmacokinetic and human factors study designs, as well as revised packaging, helping to refine the path for NDA resubmission. Aquestive reaffirmed its plan to resubmit the Anaphylm NDA in Q3 2026 and is also pursuing regulatory submissions in Canada and the European Union.
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced the successful completion of a Type A meeting with the FDA regarding the resubmission of its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film. The company reaffirmed its guidance to resubmit the Anaphylm NDA in Q3 2026 after receiving clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designs. Aquestive believes Anaphylm has the potential to be the first and only oral epinephrine rescue medication for severe allergic reactions.
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP is reminding investors of Aquestive Therapeutics (NASDAQ: AQST) about the May 4, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Aquestive made misleading statements and failed to disclose issues regarding its NDA for Anaphylm, particularly concerning human factors in its use and deployment. This follows a significant drop in Aquestive's stock price on January 9, 2026, after the FDA identified deficiencies in the NDA.
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP is investigating potential securities fraud claims against Aquestive Therapeutics, Inc. and is reminding investors of the May 4, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Aquestive failed to disclose deficiencies in its NDA for Anaphylm, specifically regarding human factors in its sublingual film's use, administration, and labeling, which led to a significant stock price drop. Investors who suffered losses between June 16, 2025, and January 8, 2026, are encouraged to contact the law firm.
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP is reminding investors of Aquestive Therapeutics (NASDAQ: AQST) that the deadline to seek lead plaintiff status in a securities class action lawsuit is May 4, 2026. The lawsuit alleges that Aquestive made false and misleading statements regarding its Anaphylm NDA, specifically downplaying human factors related to its sublingual film. Following the FDA's notification of deficiencies in January 2026, Aquestive's stock price significantly dropped.
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and certain officers. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval timeline for Anaphylm (dibutepinephrine) sublingual film, failing to disclose significant human factors risks with the New Drug Application (NDA). Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of May 4, 2026.
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Rosen Law Firm is reminding purchasers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities about the upcoming May 4, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit covers investors who bought shares between June 16, 2025, and January 8, 2026. Interested investors have the opportunity to lead the class action.
AQST Shareholder Alert: Aquestive Therapeutics, Inc.
The Gross Law Firm has issued a shareholder alert for Aquestive Therapeutics, Inc. (NASDAQ: AQST) regarding a securities class action lawsuit. Investors who purchased shares between June 16, 2025, and January 8, 2026, are encouraged to contact the firm, as Aquestive allegedly made misleading statements about its Anaphylm New Drug Application. The share price dropped significantly after the FDA identified deficiencies that delayed approval.
AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors ...
The Gross Law Firm has issued a shareholder alert for Aquestive Therapeutics, Inc. (AQST) regarding a securities class action lawsuit. Investors who purchased shares between June 16, 2021, and January 9, 2023, are encouraged to contact the firm, as the company is accused of making misleading statements concerning its New Drug Application for Anaphylm. This alleged misrepresentation led to a significant stock price drop following an FDA letter identifying deficiencies.
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and some of its officers. The lawsuit seeks damages for alleged violations of federal securities laws, claiming that the company made false and misleading statements regarding the approval timeline for its Anaphylm sublingual film. Investors who purchased Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026, are encouraged to join the case and have until May 4, 2026, to request to be appointed as lead plaintiff.
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT
Bernstein Liebhard LLP reminds investors of Aquestive Therapeutics, Inc. (AQST) about an upcoming deadline in a securities fraud class action lawsuit. Investors who purchased shares between June 16, 2025, and January 8, 2026, and lost money, are encouraged to contact the firm by May 4, 2026, to discuss their legal options, including serving as lead plaintiff. The lawsuit alleges that Aquestive made misrepresentations regarding its New Drug Application for Anaphylm.
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt
SueWallSt is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) for allegedly inadequate risk disclosures concerning its Anaphylm NDA. The lawsuit claims that the company concealed specific deficiencies in the NDA, leading to a significant stock drop, rather than providing only generic risk warnings. Investors who suffered losses between June 16, 2025, and January 8, 2026, are urged to seek a free case evaluation by the lead plaintiff deadline of May 4, 2026.
Lawsuit Alert: Investors who lost money with shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) should contact the Shareholders Foundation
A lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) on behalf of investors who purchased shares between June 16, 2025, and January 8, 2026. The lawsuit alleges violations of Federal Securities Laws due to allegedly false and misleading statements concerning the FDA approval process for Aquestive's Anaphylm New Drug Application. Investors who incurred losses are encouraged to contact the Shareholders Foundation, with a deadline to act by May 4, 2026.
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to ...
Rosen Law Firm is encouraging investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) who purchased securities between June 16, 2025, and January 8, 2026, to consider acting as lead plaintiff by the May 4, 2026 deadline. The firm alleges that Aquestive Therapeutics made false and misleading statements or failed to disclose crucial information regarding its New Drug Application for Anaphylm, particularly concerning human factors involved in its use and deployment. This purported misrepresentation led to investor damages when the true details became known.
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and its officers. The lawsuit alleges that the company made false and misleading statements regarding the approval and launch timeline for its drug Anaphylm, specifically regarding its NDA submission and the Prescription Drug User Fee Act (PDUFA) date. Shareholders who purchased Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit, with a deadline to request lead plaintiff status by May 4, 2026.
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt
SueWallSt is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) for allegedly inadequate risk disclosures regarding its Anaphylm NDA between June 16, 2025, and January 8, 2026. Shareholders who incurred losses on AQST stock are encouraged to seek a free case evaluation. The lawsuit focuses on whether the company adequately informed investors about potential deficiencies in its Anaphylm new drug application.
Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST). The lawsuit alleges that Aquestive made misleading statements regarding the approval of its New Drug Application for Anaphylm, leading to a significant drop in stock price after the FDA identified deficiencies. Investors who purchased securities between June 16, 2025, and January 8, 2026, have until May 4, 2026, to file a lead plaintiff motion.
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt
A lawsuit has been filed against Aquestive Therapeutics, Inc. (AQST) alleging that the company concealed deficiencies in its Anaphylm NDA, leading to significant investor losses. SueWallSt is investigating the adequacy of the company's risk disclosures from June 16, 2025, through January 8, 2026, after the FDA flagged issues precluding labeling discussions. Investors who suffered losses may qualify for a free case evaluation, with the lead plaintiff deadline set for May 4, 2026.
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT
Bernstein Liebhard LLP reminds investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) about an upcoming deadline for a securities fraud class action lawsuit. Investors who purchased shares between June 16, 2025, and January 8, 2026, and lost money are encouraged to join the lawsuit, which alleges misrepresentations regarding the company's New Drug Application for Anaphylm. The deadline to serve as lead plaintiff is May 4, 2026.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
Pomerantz LLP has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) on behalf of investors who suffered losses. The lawsuit alleges securities fraud and unlawful business practices following a significant stock price drop after the FDA identified deficiencies in Aquestive's New Drug Application for Anaphylm, delaying its approval. Investors who purchased Aquestive securities during the Class Period have until May 4, 2026, to seek appointment as Lead Plaintiff.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
Levi & Korsinsky is alerting investors about a securities fraud lawsuit against Aquestive Therapeutics, Inc. (AQST). The lawsuit follows Cantor's decision to slash its price target for AQST from $15 to $8, citing increased risk of delay for Anaphylm after the FDA identified deficiencies in its New Drug Application. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, experienced significant losses, prompting the firm to seek a lead plaintiff for a class action by May 4, 2026.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
The Pomerantz LLP law firm has announced a class action lawsuit against Aquestive Therapeutics, Inc. (AQST) regarding alleged securities fraud or unlawful business practices. The lawsuit follows Aquestive's stock price drop after the FDA identified deficiencies in its New Drug Application for Anaphylm, delaying its approval indefinitely. Investors who purchased Aquestive securities during the Class Period have until May 4, 2026, to seek appointment as Lead Plaintiff.
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP reminds investors of Aquestive Therapeutics (NASDAQ: AQST) about the May 4, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Aquestive and its executives made false or misleading statements regarding the company's NDA for Anaphylm, specifically by minimizing the significance of human factors related to the sublingual film's use. This news led to a significant drop in Aquestive's stock price on January 9, 2026.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
Levi & Korsinsky is alerting investors about a securities fraud lawsuit against Aquestive Therapeutics, Inc. (AQST) after a significant drop in stock value. This comes after Cantor slashed its price target for AQST following the FDA's identification of deficiencies in the company's Anaphylm NDA. The firm encourages investors who purchased AQST securities between June 16, 2025, and January 8, 2026, and experienced losses, to contact them regarding potential class action leadership, with a lead plaintiff deadline of May 4, 2026.
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its officers. The lawsuit alleges that Aquestive made false and misleading statements regarding the approval timeline and launch of its New Drug Application for Anaphylm. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit and have until May 4, 2026, to request to be appointed as lead plaintiff.
